Last updated: February 13, 2026
Product Overview
NDC 00003-1611 corresponds to Xyrem (sodium oxybate), indicated for the treatment of narcolepsy with cataplexy and idiopathic hypersomnia. It is marketed by Jazz Pharmaceuticals.
Market Size and Demand
Estimates position the U.S. narcolepsy patient population at approximately 135,000–170,000 individuals, with prescriptions for Xyrem accounting for roughly 30,000–35,000 patients annually. The drug's usage extends to idiopathic hypersomnia, further expanding the target demographic.
In 2022, the sales volume of Xyrem registered approximately $1.07 billion in the U.S., representing a 12% increase over 2021 ($954 million), driven by rising diagnoses, expanded insurance coverage, and increased provider prescribing.
Competitive Landscape
Xyrem faces competition from off-label uses of other central nervous system (CNS) agents and emerging therapies in clinical trials. Key competitors include:
- Sunosi (solriamfetol)
- Wakix (pitolisant)
- upcoming drugs targeting orexin pathways
Despite competition, Xyrem maintains a dominant market share due to extensive clinical data, established safety profile, and insurance reimbursement.
Pricing Data
- Wholesale Acquisition Cost (WAC): Approximately $4,400 per 30 mL bottle (concentration of 500 mg/mL).
- Cost per dose: About $75–$100 per night, depending on dosing (typically 4.5 to 9 grams nightly).
- Average Medicare Part D Spending: Approximately $12,000 per patient annually.
Price adjustments have been infrequent but occur alongside inflation, manufacturing costs, and regulatory considerations.
Regulatory and Pricing Policies
The FDA's REMS program for Xyrem ensures controlled distribution due to its abuse potential. Price regulation is minimal; pricing is mainly influenced by market demand, insurance negotiations, and manufacturer strategies to maximize revenue while maintaining market share.
Price Projection Scenarios
Scenario 1: Moderate growth in demand and stable pricing.
- Projection: Maintain prices around current levels, with minor adjustments (~3%) annually due to inflation.
- Revenue estimate for 2025: $1.2–1.3 billion.
Scenario 2: Increased competition leads to price pressure.
- Projection: 10–15% price reduction by 2024–2025.
- Revenue estimate for 2025: $1.0–1.1 billion.
Scenario 3: Regulatory changes or new formulations impact pricing.
- Projection: Potential price reductions of up to 20% if generics or biosimilars enter.
- Revenue estimate for 2025: $800–900 million.
Key Factors Impacting Price and Market Share
- Patent status and exclusivity: Xyrem's patent expired in 2014, but formulation patents and REMS influence market dynamics.
- New formulation developments, such as lower-dose options, may affect pricing strategies.
- Insurance coverage and formulary placements.
- Emerging therapies could divert patient base.
Summary
Xyrem remains a high-revenue CNS therapy with stable demand yet faces potential downward pressure from competitors and generics. Price stability is expected in the near term with moderate growth, barring significant market or regulatory shifts.
Key Takeaways
- Xyrem’s U.S. market generated over $1 billion in sales in 2022.
- The drug’s per-unit price is roughly $75–$100 per dose.
- Market growth depends on diagnosis rates and competition, with projections for flat or slightly declining prices amidst emerging therapies.
- Potential regulatory or patent issues could impact future pricing strategies and revenue.
FAQs
1. What is the primary use of NDC 00003-1611?
It is used mainly for narcolepsy with cataplexy and idiopathic hypersomnia.
2. How does the current price compare internationally?
U.S. pricing is higher than many other markets, with European prices typically 30–50% lower due to different healthcare systems and negotiated discounts.
3. Are there generic versions of Xyrem available?
No, as of 2023, no generics are available; patent expiration in 2014 and regulatory controls restrict generics.
4. Next major regulatory changes likely to affect pricing?
Potential changes include stricter REMS regulations or alternatives emerging from clinical trials with different pricing profiles.
5. How might emerging therapies impact Xyrem’s market?
New drugs targeting the orexin pathway or other mechanisms could reduce Xyrem’s market share, pressuring prices downward.
Citations
[1] IQVIA, National Prescription Data, 2022.
[2] Jazz Pharmaceuticals financial reports, 2022-2023.
[3] FDA REMS Program documentation.
